法舒地尔治疗蛛网膜下腔出血引起的脑血管痉挛的临床观察  

Clinical observation of fasudil in treatment of cerebral vasospasm after subarachnoid hemorrhage

作　　者：余文钦[1] 刘特炯 郑宋华 

机构地区：[1]广东省普宁市人民医院神经内科,广东普宁515300

出　　处：《中国当代医药》2013年第20期85-86,共2页China Modern Medicine

摘　　要：目的观察法舒地尔治疗蛛网膜下腔出血(SAH)引起的脑血管痉挛(CVS)的临床疗效和安全性。方法选择本院2011年2月～2012年7月收治的58例明确诊断为SAH的患者,随机分为观察组和对照组,每组29例。所有患者均在72 h内接受治疗,观察组患者在常规治疗的基础上给予法舒地尔治疗,对照组给予尼莫地平治疗,比较两组患者的临床疗效及安全性。结果观察组治疗的总有效率(96.6%)明显高于对照组(69.0%),差异有统计学意义(P<0.05);观察组不良反应较对照组少,且表现轻微。结论法舒地尔防治由SAH引起的CVS疗效确切,且不良反应少,值得推广应用。Objective To observe the efficacy and safety of fasudil in the treatment of cerebral vasospasm （CVS） after subarachnoid hemorrhage （SAH）. Methods 58 cases which diagnosed as SAH in our hospital from February 2011 to July 2012 were randomly divided into observation group and control group,each group were 29 cases.All the patients were treated in 72 h,based on traditional treatment,the observation group treated with fasudil injection,the control group treated with nimodipine.The clinical effect and safety of the two group was compared. Results The total efficien- cy of observation group （96.6%） was significantly higher than that of control group （69.0%）,the difference between the two groups was statistically significant （P〈0.05）.Adverse reactions occurred in observation group were less than that of control group. Conclusion Fasudil is safe and effective for CVS caused by SAH and with less adverse reactions, which deserves the clinical expansion.

关 键 词：蛛网膜下腔出血 法舒地尔 脑血管痉挛 

分 类 号：R743[医药卫生—神经病学与精神病学]